Aurinia Pharmaceuticals Q2 revenue up 22%, raises guidance

Aurinia Pharmaceuticals

31/07/2025 11:09

Overview

Aurinia Q2 2025 total revenue rises 22% yr/yr to $70 mln

Net income for Q2 2025 reaches $21.5 mln, up from $0.7 mln last year

Co increases share repurchase plan by $150 mln, reflecting financial confidence

Outlook

Aurinia raises 2025 revenue guidance to $260 mln-$270 mln

Company ups 2025 LUPKYNIS sales forecast to $250 mln-$260 mln

Aurinia plans clinical trials for aritinercept in autoimmune diseases

Company sees growth driven by new lupus nephritis treatment guidelines

Result Drivers

LUPKYNIS SALES - Co attributes 21% increase in net product sales to new treatment guidelines recommending LUPKYNIS as first-line therapy

COLLABORATION REVENUE - License, collaboration and royalty revenue up 55% due to manufacturing services from partner Otsuka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$66.57 mln
Q2 EPS
$0.16
Q2 Net Income
$21.51 mln
Q2 Operating Expenses
$49.92 mln
Q2 Operating Income
$20.08 mln
Q2 Pretax Profit
$22.16 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is $10.85, about 16.6% above its July 30 closing price of $9.05

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nBw74Sx5Ga

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)